Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir ‐experienced, NS5A treatment‐naive patients: findings from two randomized trials

ConclusionsIn this SOF‐experienced NS5A inhibitor‐naïve population, which included participants with cirrhosis or HCV/HIV co‐infection, high SVR12 rates were achieved.This article is protected by copyright. All rights reserved.

Source: Liver International - November 1, 2017 Category: Gastroenterology Authors: Edward Tam, Anne F. Luetkemeyer, Parvez S. Mantry, Sanjaya K. Satapathy, Peter Ghali, Minhee Kang, Richard Haubrich, Xianlin Shen, Liyun Ni, Gregory Camus, Amanda Copans, Lorenzo Rossaro, Bill Guyer, Robert S. Brown, Tags: Original Article Source Type: research